3Cannistra SA. Cancer of the ovary [J]. N Engl J Med, 1993, 329 (21): 1550-1559.
4Sironi S, Messa C, Cistaro A, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings[J]. Radiology, 2004, 233(2): 433-440.
5Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999[J]. CA Cancer J Clin, 1999, 49(1): 8-31.
6Pannu HK, Bristow RE, Cohade C, et al. PET-CT in recurrent ovarian cancer: initial observations[J]. Radiographics, 2004, 24(1): 209-223.
7Wahl RL, Hutchins GD, Buchsbaum DJ, et al. ^18F-2-deoxy-2- fluoro-D-glueose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography[J]. Cancer, 1991, 67(6): 1544-1550.
8Wahl RL, Hutchins G, Roberts J. FDG-PET imaging of ovarian cancer: initial evaluation in patients [J]. J Nucl Med, 1991, 32 (suppl): 982.
9Hubner KF, McDonald TW, Niethammer JG, et al. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[^18F] deoxyglucose (2-[^18F]FDG)[J]. Gynecol Oneol, 1993, 51(2): 197-204.
10Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck [J]. Eur J Nucl Med, 1999, 26(10): 1345-1348.
